Meeting
2022 ASCO Genitourinary Cancers Symposium
Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.
Authors
Jiaren Zhang
Weill Cornell Medicine, New York, NY
Jiaren Zhang , Bob Zimmermann , Giuseppe Galletti , Susan Halabi , Ada Gjyrezi , Qian Yang , Santosh Gupta , Andrea Sboner , Monika Anand , Daniel J. George , Simon Gregory , Seunghee Hong , Virginia Pascual , Clio P. Mavragani , Emmanuel S. Antonarakis , David M. Nanus , Scott T. Tagawa , Olivier Elemento , Andrew J. Armstrong , Paraskevi Giannakakou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 139)
DOI
10.1200/JCO.2022.40.6_suppl.139
Abstract #
139
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Association of a prostate cancer gastrointestinal transcriptional phenotype as found in clinical mCRPC samples with response to AR-targeted therapy.
First Author: Aishwarya Subramanian
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: David Johnson Einstein
Poster
2021 Genitourinary Cancers Symposium
5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC.
First Author: Martin Sjöström
Poster
2020 Genitourinary Cancers Symposium
Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.
First Author: Landon Carter Brown